Donnan Matthew, Liu Tong Lei, Gvalda Matthew, Chen Xinye, Foo Chuan T, MacDonald Martin Ian, Thien Francis
Department of Respiratory Medicine, Eastern Health, Melbourne, Victoria, Australia.
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Int J Chron Obstruct Pulmon Dis. 2025 Apr 13;20:1061-1070. doi: 10.2147/COPD.S485246. eCollection 2025.
The role of eosinophilic inflammation in exacerbations of chronic obstructive pulmonary disease (COPD) is increasingly recognised. Eosinophilic exacerbations have previously been associated with shorter hospital length of stay and lower inpatient mortality. The objective of this study was to examine clinical characteristics of hospitalised COPD exacerbations stratified by admission eosinophil count.
We performed a retrospective cohort study of exacerbations of COPD at an Australian tertiary health service between 1 October 2019 and 30 September 2020 that were identified using ICD-10 discharge codes. Patients were excluded if they received any systemic corticosteroids prior to hospitalisation. Admissions were stratified according to blood eosinophil count as high eosinophil (HE, ≥2% total white blood cell count), or low eosinophil (LE, <2%).
Four hundred and six patients were analysed. HE patients were younger (74.7 vs 77.7 years, p=0.001) and had fewer co-morbidities (1 [1-2] vs 2 [1-3], p=0.044). Patients with HE were less likely to be taking inhaled corticosteroids (59% vs 71%, p=0.017). HE exacerbations had a higher blood eosinophil count (0.31 vs 0.06 × 10/L, p<0.0001), lower total white cell count (8.45 vs 10.6, p<0.001), lower CRP (10.4 vs 26.7, p<0.001), fewer infections (29.5% vs 52.1%, p<0.001) and less oxygen requirement (35.2% vs 46.8%, p=0.036). HE exacerbations had a shorter length of stay (3.56 vs 4.40 days, p=0.047) but similar inpatient mortality.
Eosinophilic exacerbations of COPD were phenotypically different, affect a younger, less co-morbid population and were associated with shorter length of stay. This may be useful to help prognosticate clinical outcomes and guide clinical management.
嗜酸性粒细胞炎症在慢性阻塞性肺疾病(COPD)急性加重中的作用日益受到认可。此前,嗜酸性粒细胞性急性加重与较短的住院时间和较低的住院死亡率相关。本研究的目的是探讨根据入院时嗜酸性粒细胞计数分层的住院COPD急性加重的临床特征。
我们对2019年10月1日至2020年9月30日在澳大利亚一家三级医疗服务机构发生的COPD急性加重进行了一项回顾性队列研究,这些急性加重是使用国际疾病分类第十版(ICD - 10)出院编码识别的。如果患者在住院前接受过任何全身用糖皮质激素治疗,则将其排除。根据血液嗜酸性粒细胞计数将入院患者分为高嗜酸性粒细胞组(HE,≥2%白细胞总数)或低嗜酸性粒细胞组(LE,<2%)。
共分析了406例患者。HE组患者更年轻(74.7岁对77.7岁,p = 0.001),合并症更少(1[1 - 2]对2[1 - 3],p = 0.044)。HE组患者使用吸入性糖皮质激素的可能性更小(59%对71%,p = 0.017)。HE组急性加重患者的血液嗜酸性粒细胞计数更高(0.31对0.06×10⁹/L,p<0.0001),白细胞总数更低(8.45对10.6,p<0.001),C反应蛋白更低(10.4对26.7,p<0.001),感染更少(29.5%对52.1%,p<0.001),吸氧需求更少(35.2%对46.8%,p = 0.036)。HE组急性加重患者的住院时间更短(3.56天对4.40天,p = 0.047),但住院死亡率相似。
COPD的嗜酸性粒细胞性急性加重在表型上有所不同,影响的是更年轻、合并症更少的人群,且与较短的住院时间相关。这可能有助于预测临床结局并指导临床管理。